By Fineline Cube 
Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).
Financial Performance Summary – FY2025
| Metric | Amount | YOY Change (CER) |
|---|---|---|
| Total Revenue | JPY 4.5T (USD 28.5B) | -2.8% |
| Net Profit | JPY 191.8B (USD 1.21B) | +77.7% |
| Restructuring Charges (FY2026) | JPY 170B (USD 1.07B) | Planned |
| Annualized Cost Savings (by 2028) | JPY 200B+ (USD 1.26B+) | Target |
Geographic Revenue Breakdown – Market Performance
| Region | Revenue (JPY) | Revenue (USD) | YOY Growth |
|---|---|---|---|
| United States | JPY 2,164.8B | USD 13.71B | -9.0% |
| Europe & Canada | JPY 1,146.2B | USD 7.26B | +8.6% |
| Japan | JPY 433.1B | USD 2.74B | +3.5% |
| Latin America | JPY 254.1B | USD 1.61B | +7.8% |
| China | JPY 195.1B | USD 1.23B | +1.8% |
| Russia & CIS | JPY 79.7B | USD 0.50B | +10.2% |
Therapeutic Area Performance – Strategic Portfolio Analysis
| Therapeutic Area | Revenue (JPY) | Revenue (USD) | YOY Growth | Key Drivers |
|---|---|---|---|---|
| Gastroenterology (GI) | JPY 1,407.5B | USD 8.91B | +3.1% | Core growth franchise |
| Plasma-Derived Therapies (PDT) | JPY 1,057.5B | USD 6.69B | +1.9% | Stable demand |
| Rare Diseases | JPY 762.7B | USD 4.83B | -0.3% | Flat performance |
| Oncology | JPY 580.1B | USD 3.67B | +2.0% | Steady growth |
| Neuroscience | JPY 414.3B | USD 2.62B | -27.2% | Vyvanse patent cliff impact |
| Vaccines | JPY 59.6B | USD 0.38B | +5.1% | Modest growth |
Vyvanse Patent Cliff Impact & Portfolio Challenges
Neuroscience Decline Drivers:
- Vyvanse (ADHD blockbuster) facing generic competition following patent expiration
- Combined sales decline: 43% plunge for Vyvanse and other patent-expired older products in FY2025 alone
- Market dynamics: Large influx of generics eroded pricing power and market share
- Strategic consequence: Neuroscience segment transformed from growth driver to declining asset
Global Restructuring Initiative – FY2026-2028 Transformation Plan
Workforce Optimization:
- Employee Reduction: Approximately 4,500 positions eliminated globally in FY2026
- Strategic Rationale: Streamline operations, reduce management layers, centralize core corporate functions
Financial Impact Timeline:
- FY2026 Restructuring Charges: JPY 170 billion (USD 1.07 billion)
- FY2026 Gross Profit Savings: JPY 100 billion (USD 1.07 billion)
- 2028 Annualized Cost Savings Target: Over JPY 200 billion (USD 1.26 billion)
Operational Benefits:
- Enhanced organizational agility through flatter management structure
- Improved cost efficiency in core corporate functions
- Strategic reallocation of resources toward growth franchises (GI, PDT, Oncology)
Strategic Outlook & Investment Implications
Portfolio Resilience:
Despite the significant Vyvanse headwind, Takeda demonstrated strong underlying operational performance with growth in four of six therapeutic areas and five of six geographic regions. The 77.7% net profit surge reflects effective cost management and the high-margin nature of the company’s core franchises.
Geographic Diversification Success:
The -9% US decline was more than offset by strong international growth, particularly in Europe & Canada (+8.6%) and Latin America (+7.8%), demonstrating successful global diversification strategy.
Transformation Execution Risk:
The ambitious restructuring plan carries execution risk but offers substantial long-term value creation potential. Successful implementation could position Takeda for sustainable growth beyond the patent cliff period.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, restructuring outcomes, and strategic initiatives. Actual results may differ due to risks including competitive dynamics, regulatory changes, restructuring execution challenges, market conditions, and global economic factors.-Fineline Info & Tech